Overcoming cancer immune tolerance and escape

Clin Cancer Res. 2009 Feb 1;15(3):749-51. doi: 10.1158/1078-0432.CCR-08-2805.

Abstract

Although HER2/neu-targeted cancer vaccines have shown initial promise in the adjuvant setting, a therapeutic vaccine remains elusive due to the tumor escape mechanisms of established cancer. As described by Seavey et al. in this issue of CCR, a Listeria-delivered vaccine may help overcome immune tolerance, leading to an effective therapeutic vaccine.

Publication types

  • Comment

MeSH terms

  • Adjuvants, Immunologic
  • Animals
  • Bacterial Toxins / therapeutic use
  • Cancer Vaccines / therapeutic use
  • Clinical Trials as Topic
  • Genes, erbB-2
  • Genetic Vectors
  • Heat-Shock Proteins / therapeutic use
  • Hemolysin Proteins / therapeutic use
  • Humans
  • Immune Tolerance*
  • Listeria monocytogenes / immunology*
  • Mice
  • Models, Biological
  • Neoplasms / immunology*
  • Tumor Escape*
  • Vaccines, Synthetic / therapeutic use

Substances

  • Adjuvants, Immunologic
  • Bacterial Toxins
  • Cancer Vaccines
  • Heat-Shock Proteins
  • Hemolysin Proteins
  • Vaccines, Synthetic
  • hlyA protein, Listeria monocytogenes